Recent News
November 28, 2024
Contera Pharma announces first patient dosed in Phase 1b trial of CP-012, a novel therapy to treat nocturnal immobility and morning akinesia in Parkinson’s disease
Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, has announced the dosing of the first patient in…
Read more
October 18, 2024
Contera Pharma A/S closes Korean office and consolidates all activities in Denmark – 2nd announcement
Notice of Dissolution and Filing of Claims Contera Pharma A/S has decided to close the branch office in Korea and consolidate all…
Read more
Contact us
콘테라파마 본사
Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark
Thomas Sager, CEO
info@conterapharma.com
